305 related articles for article (PubMed ID: 12296858)
1. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.
Hart TK; Blackburn MN; Brigham-Burke M; Dede K; Al-Mahdi N; Zia-Amirhosseini P; Cook RM
Clin Exp Immunol; 2002 Oct; 130(1):93-100. PubMed ID: 12296858
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
3. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
[TBL] [Abstract][Full Text] [Related]
4. Pitrakinra for asthma.
Antoniu SA; Cojocaru I
Expert Opin Biol Ther; 2010 Nov; 10(11):1609-15. PubMed ID: 20923253
[TBL] [Abstract][Full Text] [Related]
5. Preclinical safety and pharmacology of an anti-human interleukin-13 monoclonal antibody in normal macaques and in macaques with allergic asthma.
Martin PL; Fisher D; Glass W; O'Neil K; Das A; Martin EC; Li L
Int J Toxicol; 2008; 27(5):351-8. PubMed ID: 19037805
[TBL] [Abstract][Full Text] [Related]
6. Regulation of murine in vivo IgG and IgE responses by a monoclonal anti-IL-4 receptor antibody.
Finkelman FD; Urban JF; Beckmann MP; Schooley KA; Holmes JM; Katona IM
Int Immunol; 1991 Jun; 3(6):599-607. PubMed ID: 1888709
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma.
May RD; Monk PD; Cohen ES; Manuel D; Dempsey F; Davis NH; Dodd AJ; Corkill DJ; Woods J; Joberty-Candotti C; Conroy LA; Koentgen F; Martin EC; Wilson R; Brennan N; Powell J; Anderson IK
Br J Pharmacol; 2012 May; 166(1):177-93. PubMed ID: 21895629
[TBL] [Abstract][Full Text] [Related]
8. Important roles of CD32 in promoting suppression of IL-4 induced immune responses by a novel anti-IL-4Rα therapeutic antibody.
Zhao J; Jiang L; Deng L; Xu W; Cao Y; Chen C; Yang Y; Wu H; Huang Y; Zhu Z; Huang H
MAbs; 2019 Jul; 11(5):837-847. PubMed ID: 30950681
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
10. Childhood asthma as an allergic disease: rationale for the development of future treatment.
Tang ML; Powell CV
Eur J Pediatr; 2001 Dec; 160(12):696-704. PubMed ID: 11795676
[TBL] [Abstract][Full Text] [Related]
11. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states.
Yang XD; Corvalan JR; Wang P; Roy CM; Davis CG
J Leukoc Biol; 1999 Sep; 66(3):401-10. PubMed ID: 10496309
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of anti-B7-H3 antibody in an ovalbumin-induced mouse asthma model.
Chen ZR; Zhang GB; Wang YQ; Yan YD; Zhou WF; Zhu C; Chen Y; Wang J; Ji W
Ann Allergy Asthma Immunol; 2013 Oct; 111(4):276-81. PubMed ID: 24054363
[TBL] [Abstract][Full Text] [Related]
13. A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation.
Brams P; Black A; Padlan EA; Hariharan K; Leonard J; Chambers-Slater K; Noelle RJ; Newman R
Int Immunopharmacol; 2001 Feb; 1(2):277-94. PubMed ID: 11360929
[TBL] [Abstract][Full Text] [Related]
14. Reassessing the Th2 cytokine basis of asthma.
O'Byrne PM; Inman MD; Adelroth E
Trends Pharmacol Sci; 2004 May; 25(5):244-8. PubMed ID: 15120489
[TBL] [Abstract][Full Text] [Related]
15. Antiallergic asthma properties of brazilin through inhibition of TH2 responses in T cells and in a murine model of asthma.
Lee CC; Wang CN; Kang JJ; Liao JW; Chiang BL; Chen HC; Hu CM; Lin CD; Huang SH; Lai YT
J Agric Food Chem; 2012 Sep; 60(37):9405-14. PubMed ID: 22920671
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
[TBL] [Abstract][Full Text] [Related]
17. Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotype antibody.
Chakraborty M; Mukerjee S; Foon KA; Köhler H; Ceriani RL; Bhattacharya-Chatterjee M
Cancer Res; 1995 Apr; 55(7):1525-30. PubMed ID: 7533665
[TBL] [Abstract][Full Text] [Related]
18. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys.
Hakimi J; Chizzonite R; Luke DR; Familletti PC; Bailon P; Kondas JA; Pilson RS; Lin P; Weber DV; Spence C
J Immunol; 1991 Aug; 147(4):1352-9. PubMed ID: 1869828
[TBL] [Abstract][Full Text] [Related]
19. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.
Kips JC; O'Connor BJ; Langley SJ; Woodcock A; Kerstjens HA; Postma DS; Danzig M; Cuss F; Pauwels RA
Am J Respir Crit Care Med; 2003 Jun; 167(12):1655-9. PubMed ID: 12649124
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
